- Home
- ONDS vs BLRX Comparison
ONDS vs BLRX Comparison
Compare ONDS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- BLRX
- Stock Information
- Founded
- ONDS N/A
- BLRX 2003
- Country
- ONDS United States
- BLRX Israel
- Employees
- ONDS N/A
- BLRX N/A
- Industry
- ONDS Telecommunications Equipment
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- BLRX Health Care
- Exchange
- ONDS Nasdaq
- BLRX Nasdaq
- Market Cap
- ONDS 52.7M
- BLRX 54.1M
- IPO Year
- ONDS N/A
- BLRX 2011
- Fundamental
- Price
- ONDS $0.93
- BLRX $0.46
- Analyst Decision
- ONDS Strong Buy
- BLRX Strong Buy
- Analyst Count
- ONDS 2
- BLRX 2
- Target Price
- ONDS $2.50
- BLRX $11.50
- AVG Volume (30 Days)
- ONDS 412.3K
- BLRX 314.6K
- Earning Date
- ONDS 11-12-2024
- BLRX 11-18-2024
- Dividend Yield
- ONDS N/A
- BLRX N/A
- EPS Growth
- ONDS N/A
- BLRX N/A
- EPS
- ONDS N/A
- BLRX N/A
- Revenue
- ONDS $9,209,335.00
- BLRX $17,048,000.00
- Revenue This Year
- ONDS N/A
- BLRX N/A
- Revenue Next Year
- ONDS $217.16
- BLRX N/A
- P/E Ratio
- ONDS N/A
- BLRX N/A
- Revenue Growth
- ONDS 0.36
- BLRX N/A
- 52 Week Low
- ONDS $0.32
- BLRX $0.43
- 52 Week High
- ONDS $1.99
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- ONDS 63.34
- BLRX 26.70
- Support Level
- ONDS $0.73
- BLRX $0.43
- Resistance Level
- ONDS $0.98
- BLRX $0.56
- Average True Range (ATR)
- ONDS 0.07
- BLRX 0.05
- MACD
- ONDS 0.02
- BLRX -0.01
- Stochastic Oscillator
- ONDS 83.37
- BLRX 12.42
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.